Pathophysiologic Differences Among Asians, Native Hawaiians, and Other Pacific Islanders and Treatment Implications

William C. Hsu, MD 1  
Edward J. Boyko, MD, MPH 2  
Wilfred Y. Fujimoto, MD 3  
Alka Kanaya, MD 4  
Wahida Karmally, DrPH, RD, CDE 5  
Andrew Karter, PhD 6  
George L. King, MD 1  
Mele Look, MBA 7  
Gertraud Maskarinec, MD, PhD 8  
Ranjita Misra, PhD 9  
Fahina Tavake-Pasi, MSc 10  
Richard Arakaki, MD 11

Differences in pathophysiology may affect the diagnosis, prevention, and treatment of diabetes in Asian Americans, Native Hawaiians, and Pacific Islanders (AANHPIs). Equally important are differences in cultural beliefs, dietary habits, and behavioral patterns among AANHPIs that require culturally effective translation of interventions into the community. These issues were discussed by clinicians and investigators at a conference held in Honolulu, Hawaii, in September 2011 with the theme “Diabetes in Asian Americans, Native Hawaiians, and Pacific Islanders: A Call to Action” by a coalition of health care organizations, clinicians, and scientists with strong interests in the topic and in the health of AANHPI populations (1).

The discourse begins with an evaluation of pathophysiologic differences, followed by a discussion of the standard diagnostic criteria and current treatment algorithms as well as dietary recommendations. The focus then shifts to various diabetes prevention studies specific to AANHPIs and their relevance to this growing ethnic minority group in America. This review concludes with two investigations that demonstrate culturally appropriate interventions and a brief description of the role played by the National Diabetes Education Program (NDEP).

PATHOPHYSIOLOGIC DIFFERENCES

Pathophysiology—type 1 diabetes

Diabetes has reached an epidemic level around the world, with most of the increase attributable to type 2 diabetes in developing Asian countries such as India and China (2). Type 1 diabetes is also increasing, although at a much less dramatic rate than type 2 diabetes and is now also increasingly associated with obesity and insulin resistance (3). The highest rates for type 1 diabetes are found in Northern European and Scandinavian countries and among the Caucasian population of the U.S. In contrast, type 1 diabetes is approximately 5 to 10 times lower in prevalence in those of Asian than those of European descent (4).

In the U.S., the incidence of type 1 diabetes is lower by two- to fivefold in blacks, Asian Americans, and Hispanics compared with Caucasians (5). A study of ethnically diverse American children with diabetes showed that most children aged <9 years had typical type 1 diabetes (6). However, among children aged 10 to 19 years, merely 10% of Caucasian children had type 2 diabetes in contrast to 40% of Asian American and Pacific Islander children (7).

In Caucasians, type 1 diabetes is closely associated with certain HLA haplotypes, such as DR3/4 and DQB1, and other genes such as insulin, cytotoxic t-lymphocyte antigen 4 (INS, CTLA4), but only ~30% of East Asians and Asian Americans have these genotypes (8). The presence of antibodies typically associated with type 1 diabetes was also low, less than 50% in various East Asian groups (9). The low occurrence of DR3 and DR4 in Asian American children with type 1 diabetes correlated with their low incidence for type 1 diabetes. However, despite the low frequency of the at-risk HLA genotype in Asians, among siblings who are positive for the genotype, in Japan for example, there is an increased rate of developing type 1 diabetes that is comparable to Caucasians (10). Other differences in genetic markers exist between Asians and Caucasians with type 1 diabetes; for example, a variant of small ubiquitin-like modifier 4 (SUMO4) was associated with diabetes in East Asians but not in Caucasians (9).

A recent study showed that type 1 diabetes can be difficult to clinically differentiate from type 2 diabetes in East Asian Americans, especially among those aged <35 years, because BMI is equally low, ~24 kg/m², in both types (11). This is very different from other ethnic groups, where the BMIs of type 2 diabetes patients are usually high and >27 kg/m². However, type 1 diabetes can be distinguished from type 2 diabetes in these patients by

From the 1Asian American Diabetes Initiative, Joslin Diabetes Center, Harvard Medical School, Boston, Massachusetts; the 2General Internal Medicine Section, Veterans Administration Puget Sound Health Care System, Seattle, Washington; the 3Department of Medicine, University of Washington, Seattle, Washington; the 4Department of Medicine, University of California, San Francisco, San Francisco, California; the 5Irving Institute for Clinical and Translational Research, Columbia University, New York, New York; the 6Division of Research, Center for Diabetes Translational Research, Kaiser Permanente Northern California, Oakland, California; the 7Center for Native and Pacific Health Disparities Research, Department of Native Hawaiian Health, John A. Burns School of Medicine, University of Hawaii at Manoa, Honolulu, Hawaii; the 8Cancer Center, University of Hawaii, Honolulu, Hawaii; the 9Department of Health and Kinesiology, Texas A&M University, College Station, Texas; the 10National Tongan-American Society, Salt Lake City, Utah; and the 11Department of Medicine, John A. Burns School of Medicine, University of Hawaii, Honolulu, Hawaii.

Corresponding author: William C. Hsu, william.hsu@joslin.harvard.edu.

Received 31 January 2012 and accepted 10 February 2012.

DOI: 10.2337/dc12-0212

A slide set summarizing this article is available online.

© 2012 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.

See accompanying commentary, p. 943, and review, p. 1181.
Pathophysiology and treatment in AANHPIs

differences in several biochemical parameters such as higher concentrations of HDL and adiponectin and lower concentrations of c-peptide in type 1 diabetes. In addition, insulin clamp studies showed significantly higher glucose disposal rates, similar to non-diabetic control subjects in type 1 diabetes than in type 2 diabetes, indicating reduced insulin sensitivity in type 2 diabetic patients even with BMIs similar to Asian Americans with type 1 diabetes. Low positivity of auto-antibodies at ~30% in Asian American patients with type 1 diabetes also raises questions about mechanisms underlying the destruction of β-cells in this population.

Pathophysiology—type 2 diabetes

The pathogenesis of type 2 diabetes is closely associated with increased body weight, obesity, sedentary lifestyle, inflammation, and insulin resistance. However, the relationship between excess adiposity and diabetes is not so straightforward in AANHPIs. Native Hawaiians and other Pacific Islanders have a higher prevalence of type 2 diabetes and are predisposed to obesity. Surprisingly, South Asians (Indians) and East Asians (Chinese, Koreans, and Japanese) typically have a lower mean BMI and waist circumference but a higher prevalence of diabetes and other metabolic conditions compared with Caucasians at similar levels of BMI and waist circumference.

To help explain this paradox, the role of body composition in diabetes risk was assessed further in multiple publications from the Japanese American Community Diabetes Study, a prospective study of second- and third-generation Japanese Americans of 100% Japanese ancestry. Results of this study have demonstrated the overriding importance of visceral fat as a risk factor for adverse metabolic outcomes such as coronary heart disease, hypertension, impaired glucose tolerance (IGT), type 2 diabetes, metabolic syndrome, and insulin resistance (12). Visceral fat measured by computed tomography as intra-abdominal fat area, in contrast to the abdominal and thigh subcutaneous fat depots, was linearly and positively associated with the risk of developing type 2 diabetes over a 10-year period (13). Several hypotheses have been advanced to explain this relationship between visceral fat accumulation and diabetes risk, including deposition of free fatty acids mobilized from visceral fat into the liver’s portal circulation and the presence of adipocyte-associated inflammatory markers (14).

In addition, a cross-sectional comparison of Caucasians in Pittsburgh and native Japanese found a higher mean visceral fat area in each quartile of waist circumference that reached statistical significance in two quartiles (15). In another cross-sectional comparison, Filipino women in California with a normal Asian-adjusted BMI (<23 kg/m²) similarly had a greater volume of intra-abdominal fat compared with white or African American women also with a normal BMI (<25 kg/m²) (16). The available evidence therefore argues that Asian ethnicity may be predisposed to greater deposition of fat in the visceral depot.

Little is known about differences in regional fat distribution in other Asian or Pacific Islander or Native Hawaiian ethnic groups. At a BMI cut point of 30 kg/m² in European men and women residents of New Zealand that corresponded to a mean percentage of body fat by dual X-ray absorptiometry (DXA) of 28.7% and 42.5%, respectively, the same percentage of body fat at higher BMI cut points was found in Maori and Pacific Islander men (31.3, 34.1) and women (33.1, 35.0) (17).

Differences in body composition have been examined to explain variation in type 2 diabetes prevalence by ethnicity. In a logistic model predicting type 2 diabetes prevalence by ethnicity among Filipino, white, and African American women, adjustment for visceral fat did not explain the higher odds of diabetes associated with ethnicity, because Filipino women continued to have a statistically significant 7.51-fold and 2.30-fold increased odds of diabetes (16). In that study, ethnic differences in diabetes prevalence by ethnicity could not be completely explained by body composition and other measured lifestyle characteristics.

An analysis of the Hawaii component of the Multiethnic Cohort allowed a direct comparison of the influence of excess body weight and weight change on diabetes incidence in Caucasians, Native Hawaiians, and Japanese Americans (18,19). After a total follow-up time of 1,119,224 person-years, 11,838 incident diabetes cases were identified, with an annual incidence rate of 10.4/1,000 person-years. Native Hawaiians had the highest rate at 15.5, followed by Japanese Americans (12.5) and Caucasians (5.8); the adjusted hazard ratios (HRs) were 2.65 for Japanese Americans and 1.93 for Native Hawaiians compared with Caucasians (18). BMI was positively related to incidence in all ethnic groups (Fig. 1). Compared with the lowest category of BMI, the respective HRs at BMIs of 22.0–24.9, 25.0–29.9, and ≥30.0 kg/m² were 2.10, 4.12, and 9.48. The risk was highest for Japanese Americans and intermediate for Native Hawaiians in each BMI category. Similar to the effects of BMI, diabetes risk was greatest for Japanese Americans, intermediate for Native Hawaiians, and lowest for Caucasians in each weight-gain category (Fig. 2). The partial population-attributable risk for BMI in men was 65, 60, and 38% for Caucasians, Native Hawaiians, and Japanese Americans, respectively, and 64, 67, and 38% for women, but the ethnic differences were not statistically significant.

![Figure 1](https://care.diabetesjournals.org/article-figures/1190-Figure1.png)  
**Figure 1**—Diabetes risk by BMI category in the Hawaii component of the Multiethnic Cohort Study. The reference group is Caucasians in the lowest BMI category.
DIABETES COMPLICATIONS—In previous reports, aggregate data for Asians and Pacific Islanders with health insurance coverage showed a significantly lower incidence of cardiovascular disease and lower-extremity amputation (LEA) and higher end-stage renal disease (ESRD) rates over 2 years of follow-up compared with Caucasians (20). To obtain disaggregated data, a prospective cohort study was done (1996–2006) of 64,211 diabetic patients enrolled in the Kaiser Permanente Northern California Diabetes Registry, including 40,286 Caucasians, 8,668 blacks, 7,763 Latinos, 3,572 Filipinos, 1,823 Chinese, 951 Japanese, 593 Pacific Islanders, and 555 South Asians (21). Incidence rates were calculated after 7.2 ± 3.3 years of follow-up, and Cox proportional hazard models were created, adjusted for age, educational attainment, English proficiency, neighborhood deprivation, BMI, smoking, alcohol use, exercise, medication adherence, type and duration of diabetes, HbA1c, hypertension, estimated glomerular filtration rate, albuminuria, and LDL cholesterol. Incidences of myocardial infarction (MI), congestive heart failure (CHF), stroke, ESRD, and LEA were age- and sex-adjusted. The range of CHF unadjusted incidence rates among the four Asian groups was narrower than for MI (5.9–7.6), but the aggregated rate of 7.0 was lower than in Caucasians (13.0) and Pacific Islanders (9.2). Fully adjusted models showed no significant differences among these groups compared with Caucasians. The fully adjusted models for stroke showed a similar pattern as with CHF.

For ESRD, aggregating the Asian groups obscured the differences among the groups. The age- and sex-adjusted rate for the aggregate was 2.9 and slightly higher than in Caucasians (2.4), but the rates ranged from 1.1 in South Asians to 3.9 in Filipinos. In Pacific Islanders, the rate was even higher (5.0). The fully adjusted models showed higher rates than in Caucasians in all except for South Asians.

Asians had a ~60% lower incidence of LEA compared with Caucasians or Pacific Islanders. The age- and sex-adjusted rates ranged from 0.7 to 1.3 in Asians, compared with 2.4 in Caucasians and 2.6 in Pacific Islanders. The fully adjusted models showed similar differences.

In summary, the incidence rates in Chinese, Japanese, and Filipinos were similar for most complications in this cohort with health care insurance. For the three macrovascular complications, Pacific Islanders and South Asians had rates similar to Caucasians. The incidence of complications varied dramatically among the Asian subgroups and highlights the value of a more nuanced ethnic stratification for public health surveillance and etiologic research.

TAILORING DIAGNOSIS, PREVENTION, AND TREATMENT TO REFLECT ETHNIC DIFFERENCES

Diagnosis
Current criteria for the diagnosis of diabetes include fasting plasma glucose ≥126 mg/dL, 2-h plasma glucose ≥200 mg/dL during an oral glucose tolerance test (OGTT), a random plasma glucose >200 mg/dL with classic symptoms, and HbA1c of ≥6.5%. In a cross-sectional study of Japanese Americans, OGTT assessment of 503 individuals with normal fasting glucose identified 176 with IGT and 20 with glucose levels in the diabetic range (22). These data raise the concern that diagnosis by fasting glucose alone fails to detect many Asian Americans with abnormal glucose tolerance who already have less favorable cardiovascular risk profiles. Similarly, the Diabetes Epidemiology: Collaborative Analysis of Diagnostic Criteria in Asia (DECODA) study, involving 11 population-based studies from Asia, showed that of 1,215 subjects diagnosed with diabetes by fasting plasma glucose or OGTT, only 449 met both criteria, a concordance of 37% (23). Because impaired fasting glucose (IFG) and IGT both demonstrate some features of β-cell defect and insulin resistance, but in differing degrees, the concordance between the two categories is expected to be limited (24).

In 2009, an international expert committee recommended the use of HbA1c ≥6.5% as a diagnostic criterion for diabetes
Pathophysiology and treatment in AANHPIs

(25). A study of Filipino Americans, Japanese Americans, and Native Hawaiians showed that the sensitivity and specificity of HbA1c $\geq 6.5\%$, compared with diabetes defined by OGTT, was 40.0 and 96.8\%, respectively, and by fasting plasma glucose was 68.9 and 95.3\%, respectively (26,27). These data indicate using HbA1c alone as a diagnostic test has high specificity but might delay the diagnosis of type 2 diabetes among AANHPIs.

These diagnostic considerations are particularly significant in Asian Americans because they have higher risks for diabetes, often present without overt signs of obesity, and may be misdiagnosed if a test with low sensitivity is used. Although more cumbersome and less replicable, the OGTT is the most robust but underused diagnostic standard for diabetes in Asian Americans.

Treatment

On the basis of clinical trials data and collective clinical experience, the American Diabetes Association/European Association for the Study of Diabetes and American Association of Clinical Endocrinologists have issued sets of recommendations for initiating and adjusting therapy for type 2 diabetes (28,29). A criticism of these algorithms—their failure to address fundamental pathophysiology—is especially relevant to a discussion of the treatment of diabetes in AANHPIs (30). The unique features of diabetes pathophysiology among subgroups within this very heterogeneous population may indicate a need for different treatment guidelines.

Moreover, the inherent methodologic issues of collection, analysis, and reporting of granular data in the AANHPI population means that there exist too few AANHPI subjects in clinic trials to determine the efficacy or safety of glucose-lowering drugs specific to the population (31). Some have advocated borrowing drug trial data from Asian countries in lieu of obtaining data from the Asian American population, but critics argue that despite identical genetic makeup between Asians and Asian Americans, environmental and epigenetic factors could alter physiologic responses.

Given these deficiencies, there are simply not enough data at present to develop separate treatment guidelines for this highly heterogeneous population. Nonetheless, some cultural factors, such as food, must be taken into account.

**DIETARY GUIDELINES FOR AMERICANS, 2010 (DGA 2010): CAN THEY ACCOMMODATE ETHNIC AND TRADITIONAL FOOD PREFERENCES?**

—Food plays a significant role when considering the prevention and treatment of diabetes in AANHPIs. Food selection is often guided by religious beliefs, folklore, food availability, taste, and varying approaches to diet therapy. Environmental changes and increased acculturation can have a negative impact on the weight and health of AANHPIs (32,33).

The DGA 2010 (34) provide evidence-based recommendations for individuals aged 2 years and older that accommodate the food preferences, cultural traditions, and customs of the many diverse groups in the U.S. The two overarching concepts addressed in the guidelines are: Maintain caloric balance over time to achieve and sustain a healthy weight. To control the obesity epidemic and prevent associated risk factors, Americans are advised to decrease their intake of calories and increase physical activity. The strategies recommended are: 1) monitor food and beverage intake; 2) reduce portion sizes; 3) choose smaller portions or lower calorie options when eating out; 4) use food-preparation techniques that decrease fat intake such as baking, broiling or sautéing with minimal amounts of unsaturated oils in place of butter, ghee, lard, coconut oil, and milk (sources of saturated fatty acids), and trans-fats; and 5) limit television screen time. Although food ingredients may differ according to cultural practices, these recommendations are generally applicable to the AANHPI population. As already noted, the specific weight targets are lower for Asian Americans.

Focus on consuming nutrient-dense foods and beverages. Americans are advised to consume less sodium, fat, refined grains, sugar, and alcohol-containing foods and beverages and replace them with vegetables, fruits, whole grains, lean meats, poultry without skin, seafood, very low-fat dairy, beans and peas, nuts, and seeds. If alcohol is consumed, the guidelines state up to two drinks per day for men and up to one drink per day for women. To reduce high blood pressure risk, the general recommended sodium intake is $\leq 2,300$ mg/day. For individuals more sensitive to increased sodium intake, the recommendation is to lower it to 1,500 mg/day. High salt consumption is common in many Asian cultures because many foods are pickled or preserved in salt or in high-sodium sauces; therefore, the use of these condiments should be reduced.

The U.S. Department of Agriculture’s “MyPlate” is a practical tool to help Americans make appropriate food choices and control portion sizes. MyPlate illustrates the five food groups using a familiar mealtime visual, a plate setting. In MyPlate, half of the plate should be vegetables and fruits and the other half allotted to grains and proteins. An additional portion of dairy is also recommended. The limitation for this sizing approach is evident in some Asian cultures because bowls or multiple plates are used in place of one plate. Food is also often shared in communal plates from which individuals take bite sizes of food. These eating practices present major challenges to traditional teaching and counting of carbohydrates (35). In addition, many Asians may be more concerned with food texture, flavor, or aroma than what dietitians typically focus on such as the macronutrient composition or carbohydrate counting. AANHPIs also have strong beliefs on the healthfulness of foods in health and disease (36). These concepts are not familiar to Western culture. In summary, the principles outlined in DGA 2010 are applicable to the AANHPI community, but their practical implementation will require cultural adaptation.

**DIABETES PREVENTION**

No study of diabetes prevention has been specifically directed to Asians or Pacific Islanders in the U.S. However, a subset of 142 participants (4.4\% of the cohort) in the Diabetes Prevention Program (DPP) was AANHPI (37). Although their sample size was small, results among AANHPIs are still worth noting. AANHPIs showed a higher conversion rate per year in the placebo group of 12.1\% versus 10.3\% in Caucasians, despite lower mean weight and BMI. However, compared with Caucasians, AANHPI showed greater risk reduction with lifestyle intervention (71\% vs. 51\%) and metformin (38\% vs. 24\%). Assessment of potential factors that could explain the differences in conversion rates and risk reductions, such as age, weight, physical activity level, family history, and visceral adiposity, could not be evaluated.

Other lifestyle intervention studies among Asians have been performed in Asia, and the results are reported in Table 1. Of interest are the varied diabetes conversion and intervention risk reduction rates among these different populations (38–40).
Responses to medication for diabetes prevention, including differences in side effects, also vary among Asians, perhaps due to differences in diabetes pathophysiology. In contrast to the response among AANHPi in the DPP, metformin failed to show a large reduction of diabetes incidence among Chinese and Indians (41,42), although the Indian Diabetes Prevention Programme showed that low-dose metformin reduced diabetes incidence by 26%, similar to lifestyle intervention. Interestingly, the addition of metformin to a lifestyle intervention failed to show further risk reduction. Because of the Asian custom of having high carbohydrate consumption with each meal, addressing postprandial hyperglycemia appears to be a unique and effective intervention among Asians. A diabetes prevention study in Japan using an α-glucosidase inhibitor showed a risk reduction of 58% (43). Mixed results have been noted with the use of thiazolidinediones. Pioglitazone did not further reduce diabetes incidence when added to lifestyle intervention in the Indian Diabetes Prevention Programme, and rosiglitazone treatment among the Indian cohort of the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) Trial showed less risk reduction than other populations (40% vs. 60%) (44,45).

**COMMUNITY-BASED INTERVENTION IN ASIAN INDIONS**—Asian Indians (AIs) in the U.S. and other westernized countries have high rates of type 2 diabetes (46). Insulin resistance is highly prevalent in AI migrants, despite low rates of obesity (47). Increased urbanization and socioeconomic and lifestyle transitions are associated with the rapid rise of type 2 diabetes in urban and rural India as well as in AI immigrants to the U.S. (48).

To assess the prevalence of diabetes in AIs living in the U.S., a study of 1,038 randomly selected AI adults was undertaken at seven U.S. urban sites (46). Participants were a mean age of 45.7 ± 12.8 years, length of residence in the U.S. was 18.5 ± 11.04 years, and BMI was 25.4 ± 3.7 kg/m². Most (60%) were not vegetarian, and 52% reported dietary acculturation since moving to the U.S. Family history of diabetes (siblings and parents) was reported by 57%. The prevalence of diabetes was 17.4% (14.0% with known diabetes and 3.4% undiagnosed diabetes), prevalence of prediabetes was 32.9%, and prevalence of the metabolic syndrome, using International Diabetes Federation criteria, was 38.2%. CVD risk factors were also observed, including high levels of triglycerides, total cholesterol, LDL cholesterol, homocysteine, and C-reactive protein, and low levels of HDL cholesterol.

Serving as a model for effective community-based intervention, a 7-month community-based participatory diabetes prevention and management program was initiated in South India (49). Trained community health workers provided an educational intervention to 703 village inhabitants, consisting of adults and youth, aged 10–92 years. Mean BMI in the adult population was 20.6 ± 3.8 kg/m², 11.6% were overweight, and 16.4% were obese. Mean daily caloric intake was 1,636.1 ± 683.1 kcal in adults and 1,370.5 ± 536.2 kcal in youth. High-risk participants were provided one-on-one education and counseling for blood glucose management by a certified diabetes educator. Culturally and linguistically appropriate health education messages addressed diet, physical activity, and knowledge of the disease. The age-specific prevalences of diabetes and IFG were 5.1% and 13.5% among adults and 0% and 5.1% among youth, respectively.

Intervention successfully reduced fasting blood glucose levels among adults, youth, and high-risk groups of IFG and type 2 diabetes: 3% in the adults, 11% in IFG adults, 17% in IFG youth, and 25% among adults with type 2 diabetes. A significant reduction in all obesity parameters was also noted among adults and IFG adults, and improvements in dietary fiber and protein also occurred among adults (P = 0.001). Lower intake of dietary fiber, high blood pressure, and obesity significantly predicted higher blood glucose levels (R² = 0.14, F = 4.54, P = 0.001). Although the intervention did not change dietary patterns in youth, there was an increase in the knowledge level of the participants (P = 0.013).

This study showed that a community-based participatory approach to lifestyle intervention successfully improved blood glucose levels, fiber intake, and obesity risk factors in rural India and may serve as a prototype for similar programs among AIs living in the US.

**CULTURE-BASED DIABETES EDUCATION AND SELF-MANAGEMENT AMONG NATIVE HAWAIIANS AND PACIFIC ISLANDERS**—Diabetes disproportionately affects Pacific people, such as Native Hawaiians, where prevalence rates can be four times higher than in the general U.S. population (50). Community organizations in collaboration with the University of Hawai’i’s Center for Native and Pacific Health Disparity Research developed innovative diabetes self-management education programs that combine classroom teaching with reconnecting participants to the land. For Pacific people, relationship to land is a deep and enduring part of their identity, history, and spiritual beliefs. Pacific Islanders, such as Native Hawaiians, view the origin of man as arising from the land or from a product of the land, metaphorically described as a familial relationship between plants and humans and a filial relationship humans have with the land. The land is seen as the provider of substance for the body and spirit. Aloha ‘aina (love for the land) is a recurring theme in the poetry, dance, and music of Pacific people that can be traced back at least 1,000 years.

Culture-based education is the grounding of instruction in the values, norms, knowledge, beliefs, practices, experiences, and language of the students’ culture. Also known as culturally responsive schooling, it is a framework for teaching promoted by educational scholars and indigenous leaders for the past 40 years (51). The four community-based health organizations in Hawai’i with diabetes educational programs centered around reconnecting to the land and values of aloha ‘aina included three community health clinics and a federally established Native Hawaiian Health Care System site.

The Healthy Eating and Lifestyle Program (HELP) and Mai ka Malā ‘ai (MALA) are diabetes self-management classes for Pacific people that combine classroom education with reconnecting to the land to grow produce. The program participants have type 2 diabetes and were referred by their primary care physicians because of poor self-management. Most participants are from Polynesian or Micronesian island groups or nations, including Hawai’i, Tonga, Samoa, Marshall Islands, and Chuuk. The classroom curricula for each program, developed by each organization’s nutritionist, were built around evidence-based findings for diabetes self-care education. HELP is a 6-month program, with a monthly 2-h classroom session and optional biweekly communal gardening. MALA is a 10-week program with weekly 90-min classroom sessions and optional backyard gardening. Both programs extensively incorporate aspects of culture-based education into their curricula and teaching strategies.

Clinical measurements (weight, blood pressure, HbA1c, and cholesterol) were
## Table 1 — Diabetes prevention studies in Asians and Pacific Islanders

<table>
<thead>
<tr>
<th>Cohort characteristics</th>
<th>Interventions</th>
<th>Weight changes during study</th>
<th>Diabetes conversion rate (control)</th>
<th>Relative risk reduction vs. control</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Lifestyle studies</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diabetes Prevention Program (U.S.) (37)</td>
<td>AANHPI IGT and FPG &gt;95 BMI 29.3 kg/m² 57 lifestyle 49 placebo</td>
<td>Weight loss &gt;7% Physical activity of &gt;150 min/week</td>
<td>Lifestyle: −5.6 kg Placebo: −0.1 kg</td>
<td>12.1%/year Lifestyle, 71%</td>
</tr>
<tr>
<td>China Da Qing Study (38)</td>
<td>IGT BMI 26 kg/m² 30 diet 141 exercise 126 diet + exercise 133 control</td>
<td>Clinic-based Diet: high fiber, reduced sugar and alcohol Reduced total calories in obese group</td>
<td>Diet, exercise, and diet + exercise: &lt; −1 kg Control: −0.89 kg</td>
<td>66.7%/6 years Diet, 31% Exercise, 46% Diet + exercise, 42%</td>
</tr>
<tr>
<td>Japan Diabetes Prevention Study (39)</td>
<td>IGT in men BMI 24 kg/m² 356 control 102 active</td>
<td>Target BMI Active: &lt;22 Control: &lt;24 Low-fat (5–10% total calories)</td>
<td>Active: −2.18 kg Control: −0.39 kg</td>
<td>9.3%/4 years 67.4%</td>
</tr>
<tr>
<td>Zensharen Study (40)</td>
<td>IFG and IGT BMI 27 kg/m² 311 intervention 330 control</td>
<td>For all participants: Weight loss &gt;5% Walking &gt;60 min/month</td>
<td>Intervention: −2.5 kg Control: −1.1 kg (12 months)</td>
<td>5.8%/year 44%</td>
</tr>
<tr>
<td>Indian Diabetes Prevention Programme (41)</td>
<td>IGT BMI 26 kg/m² 133 active 136 control</td>
<td>Lower total calories Increase fiber Less sugar</td>
<td>Active: &lt;1-kg gain (24 months) Control: &lt;1-kg gain</td>
<td>55%/3 years 28.5%</td>
</tr>
<tr>
<td><strong>Medication studies</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diabetes Prevention Program (U.S.) (37)</td>
<td>AANHPI IGT and FPG &gt;95 BMI 29.3 kg/m² 36 metformin 49 placebo</td>
<td>Metformin (850 mg b.i.d.)</td>
<td>Metformin: −2.1 kg Placebo: −0.1 kg</td>
<td>7.5%/year 38%</td>
</tr>
</tbody>
</table>

Continued on p. 1195
A NATIONAL PROGRAM FOR DIABETES PREVENTION AND COMMUNITY INTERVENTION

Table 1—Continued

<table>
<thead>
<tr>
<th>Cohort characteristics</th>
<th>Interventions</th>
<th>Weight changes during study</th>
<th>Diabetes conversion rate (control)</th>
<th>Relative risk reduction vs. control</th>
</tr>
</thead>
<tbody>
<tr>
<td>China Da Qing Study (38)</td>
<td>IGT BMI 26 kg/m² 42 metformin 43 placebo</td>
<td>Metformin (250 mg b.i.d.)</td>
<td>Metformin: −1.4 BMI change Placebo: +0.4 BMI change</td>
<td>14%/year</td>
</tr>
<tr>
<td>Indian Diabetes Prevention Programme (metformin) (41)</td>
<td>IGT BMI 26 kg/m² 133 metformin 129 lifestyle + metformin 136 placebo</td>
<td>Metformin (250 mg b.i.d.) Lifestyle intervention + metformin (250 mg b.i.d.)</td>
<td>Metformin: no change Lifestyle + metformin: no change Control: no change</td>
<td>55%/3 years</td>
</tr>
<tr>
<td>Indian Diabetes Prevention Programme (pioglitazone) (44)</td>
<td>IGT BMI 26 kg/m² 204 lifestyle + pioglitazone 203 placebo</td>
<td>Lifestyle intervention + pioglitazone (30 mg daily)</td>
<td>Pioglitazone: +0.68 kg Control: −0.40 kg</td>
<td>10.5%/year</td>
</tr>
<tr>
<td>Asian Indian Cohort of the DREAM Trial (45)</td>
<td>IGT BMI 28 kg/m² 332 rosiglitazone 330 placebo</td>
<td>Rosiglitazone (8 mg daily)</td>
<td>2-kg weight gain for all participants</td>
<td>8%/year</td>
</tr>
<tr>
<td>Japan Voglibose Study (43)</td>
<td>IGT BMI 26 kg/m² 112 active 110 placebo</td>
<td>Voglibose (0.2 mg t.i.d.)</td>
<td>Not available</td>
<td>3.1%/year</td>
</tr>
</tbody>
</table>

**Table 1**

<table>
<thead>
<tr>
<th>Cohort characteristics</th>
<th>Interventions</th>
<th>Weight changes during study</th>
<th>Diabetes conversion rate (control)</th>
<th>Relative risk reduction vs. control</th>
</tr>
</thead>
<tbody>
<tr>
<td>China Da Qing Study (38)</td>
<td>IGT BMI 26 kg/m² 42 metformin 43 placebo</td>
<td>Metformin (250 mg b.i.d.)</td>
<td>Metformin: −1.4 BMI change Placebo: +0.4 BMI change</td>
<td>14%/year</td>
</tr>
<tr>
<td>Indian Diabetes Prevention Programme (metformin) (41)</td>
<td>IGT BMI 26 kg/m² 133 metformin 129 lifestyle + metformin 136 placebo</td>
<td>Metformin (250 mg b.i.d.) Lifestyle intervention + metformin (250 mg b.i.d.)</td>
<td>Metformin: no change Lifestyle + metformin: no change Control: no change</td>
<td>55%/3 years</td>
</tr>
<tr>
<td>Indian Diabetes Prevention Programme (pioglitazone) (44)</td>
<td>IGT BMI 26 kg/m² 204 lifestyle + pioglitazone 203 placebo</td>
<td>Lifestyle intervention + pioglitazone (30 mg daily)</td>
<td>Pioglitazone: +0.68 kg Control: −0.40 kg</td>
<td>10.5%/year</td>
</tr>
<tr>
<td>Asian Indian Cohort of the DREAM Trial (45)</td>
<td>IGT BMI 28 kg/m² 332 rosiglitazone 330 placebo</td>
<td>Rosiglitazone (8 mg daily)</td>
<td>2-kg weight gain for all participants</td>
<td>8%/year</td>
</tr>
<tr>
<td>Japan Voglibose Study (43)</td>
<td>IGT BMI 26 kg/m² 112 active 110 placebo</td>
<td>Voglibose (0.2 mg t.i.d.)</td>
<td>Not available</td>
<td>3.1%/year</td>
</tr>
</tbody>
</table>
diabetes and their families, health care providers, community-based lay workers, businesses and work sites. Some of the resources on the importance of early glycemic control, diabetes and heart disease, diabetes self-management, and diabetes prevention are available in 13–15 AANHPI languages. To improve culturally appropriate outreach to communities, CDC/NDEP funded organizations serving ethnic/racial minority communities: AAPCHO, National Asian Women’s Health Organization, Khmer Health Advocates, and Papa Ola Lokahi. These organizations further adapted NDEP materials and determined culturally appropriate ways to reach the communities.

There are many other resources that are relevant to AANHPI populations such as tips for selecting foods at buffets, a grocery list for Asian foods, and a range of media articles. Materials for professionals serving AANHPI populations also included “Silent Trauma,” a white paper for health care professionals, community leaders, and policy makers. Its recommendations deal specifically with issues and barriers to refugees and include information on reducing the impact of diabetes in Southeast Asians in the U.S. Another resource is the “Capacity Building Tool Kit,” based on AAPCHO’s A Community Approach to Responding Early (CARE) model using stages of change and provides a framework to help build diabetes outreach capacity in community-based organizations serving AANHPI population.

CONCLUSIONS—The symposium from which data from this review was discussed (“Diabetes in Asian Americans, Native Hawaiians, and Pacific Islanders: A Call to Action”) was “a call to action” to address diabetes among AANHPI populations and highlighted the specific differences, enormous diversity, and broad challenges that face health care providers as well as patients with diabetes (Table 2). With an emphasis on developing an action plan and policy through evidence-generated understanding of the problems of diabetes within the AANHPI, general consensus was attained on several items.

First and foremost is the need for better characterization of the burden of diabetes and diabetes-related complications such as ESRD and accurate and complete population-based data. A greater research effort and increased funding should be provided to improve our understanding of the differences in diabetes pathophysiology in AANHPI.

Next is the need to enrich clinical research with better representation by AANHPI individuals. The current standards used by health care providers and payers for diabetes management for the AANHPI population are based on guidelines derived from clinical trials that did not include very many AANHPI individuals. Their disproportionately higher diabetes rates warrant the need for greater inclusion of AANHPIs in research so that results can be meaningfully interpreted. Larger clinical trials should include minority groups beyond their national population representation because the disease is disproportionately prevalent.

Another consensus was that aside from the need for more epidemiologic and clinical data, our current understanding of diabetes in AANHPIs should be resonated across the country. Many AANHPI patients with diabetes receive their care from non-AANHPI physicians. Health care providers need to be informed about the physiologic and cultural characteristics of diabetes in this population: diabetes risk may be associated with lower BMI and weight; the association of smaller degrees of visceral adiposity with greater insulin resistance and metabolic syndrome; higher carbohydrate consumption requires greater need to address postprandial hyperglycemia; and various cultural barriers to therapy and nutritional recommendations.

A final outcome from this symposium was the importance and effectiveness of community-based interventions. The diversity among AANHPIs precludes the use of any “one shoe fits all” recommendation or intervention. Improving diabetes care and reducing risk factors that contribute to diabetes and diabetes complications need to be tailored and made specific to a given population. The two contrasting interventions in India and Native Hawaiian communities demonstrate the effectiveness of “including the people” in their own care. Developing these programs may be an enormous and potentially complex undertaking, given the diversity of communities within the AANHPI population, but could ultimately result in cost-saving. An example is diabetes prevention. It is clear from all the available clinical trials and translational efforts among AANHPIs that lifestyle intervention directed toward weight loss and increasing physical activities will reduce diabetes incidence. An AANHPI initiative that targets lifestyle intervention in at-risk individuals and offered through community-based programs should be seriously considered as a priority within a national program for reducing the burden of diabetes.

Acknowledgments—This article was made possible in part by Award P20MD000173 from the National Center on Minority Health and Health Disparities. This work was partly supported by National Institutes of Health Grants DK-31170, HL-49293, and DK-02654; by facilities and services provided by the Diabetes and Endocrinology Research Center (DK-17047), Clinical Nutrition Research Unit (DK-35816), and the General Clinical Research Center (RR-00037) at the University of Washington. The VA Puget Sound Health Care System provided support for E.J.B.’s involvement in this research.

W.C.H. is on the advisory board for Novo Nordisk. No other potential conflicts of interest relevant to this article were reported.

W.C.H. and R.A. researched data, contributed to discussion, and wrote, reviewed, and edited the manuscript. E.J.B., W.Y.F., A.Kan., W.K., A.Kat., G.L.K., M.L., G.M., R.M., and F.T.-P. researched data and wrote, reviewed, and edited the manuscript.


The authors are grateful to the King County Japanese-American community for their support and cooperation.

<table>
<thead>
<tr>
<th>Table 2—Suggested next steps from the Symposium</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. More accurately characterize the burden of diabetes and diabetes-related complications based on complete and population-based data for AANHPIs</td>
</tr>
<tr>
<td>2. Enrich clinical research with more representation by AANHPI individuals</td>
</tr>
<tr>
<td>3. Educate health care providers across the country about the current understanding of the pathophysiology and cultural factors associated with diabetes in AANHPIs</td>
</tr>
<tr>
<td>4. Develop more community-based diabetes prevention or intervention programs and tailor diabetes care to the AANHPI community through a culturally effective approach</td>
</tr>
</tbody>
</table>

**Pathophysiology and treatment in AANHPIs**
References


